Skip to main content
Article thumbnail
Location of Repository

A review of quetiapine in combination with antidepressant therapy in patients with depression

By Ella J Daly and Madhukar H Trivedi
Topics: Expert Opinion
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2656328
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2005). A comparison of unipolar depression treatment using antidepressants alone versus using antidepressants in combination with quetiapine. Eur Neuropsychopharmacol,
    2. (2001). A novel augmentation strategy for treating resistant major depression.
    3. (2004). A prospective randomized single-blind, multicenter trial comparing the effi cacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety.
    4. (2007). A randomized, doubleblind comparison of olanzapine/fl uoxetine combination, olanzapine, and fl uoxetine in treatment-resistant major depressive disorder.
    5. (2006). A randomized, doubleblind comparison of olanzapine/fl uoxetine combination, olanzapine, fl uoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety,
    6. (2005). A randomized, doubleblind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.
    7. (2006). Add-on quetiapine for bipolar depression: a 12-month open-label trial.
    8. (1998). Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression.
    9. (2001). Addition of olanzapine for treatment-resistant depression.
    10. (2005). Adjunctive quetiapine for treatmentresistant adolescent major depressive disorder: A case series.
    11. (2003). Adjunctive ziprasidone in treatment-resistant depression: A pilot study (Abstract
    12. (2002). An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy.
    13. (1998). Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors.
    14. (2005). Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder.
    15. (2005). Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder.
    16. (1998). Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders.
    17. (2005). Atypical antipsychotics in bipolar depression: Potential mechanisms of action.
    18. (2007). Augmentation of antidepressants with atypical antipsychotic medications for treatmentresistant major depressive disorder: a meta-analysis.
    19. (2004). Augmentation with risperidone in chronic resistant depression: A double-blind placebocontrolled maintenance trial. Neuropsychopharmacology,
    20. (2006). Beyond effi cacy: The STAR*D trial.
    21. (2001). Clinical guidelines for the treatment of depressive disorders IV. Medications and other biological treatments.
    22. (1993). Clinical practice guideline. depression in primary care: volume 2: treatment of major depression.
    23. (2000). Clinical predictors of acute response with quetiapine in psychotic mood disorders.
    24. (2002). Clinical use of quetiapine in disease states other than schizophrenia.
    25. (2003). Consensus Group of the British Association of Psychopharmacology.
    26. (1998). Depressive signs and symptoms in schizophrenia – A prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry,
    27. (2000). Diagnostic and statistical manual of mental disorders – text revision.
    28. (1996). Dopamine receptors and brain function.
    29. (2007). Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum Psychopharmacol,
    30. (2003). Effi cacy of olanzapine and olanzapine-fl uoxetine combination in the treatment of bipolar I depression.
    31. (2002). Effi cacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis.
    32. (2006). Effi cacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebocontrolled study (the BOLDER II study).
    33. (2005). Effi cacy, safety and tolerability of quetiapine: short-term high doses with long-term follow-up.
    34. (2006). Essentials of Clinical Psychopharmacology.
    35. Exp Ther,
    36. (1985). Frequency and differential-diagnosis of depressive syndromes in schizophrenia.
    37. (1997). In vitro prediction of potential metabolic drug interactions for Seroquel. Schizophr Res,
    38. (2005). Issues in treatment-resistant depression.
    39. (2001). Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: Implications for antipsychotic drug treatment.
    40. (2002). Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions.
    41. (2004). Long-term weight change with quetiapine treatment in schizophrenia: a comprehensive data review [poster] American College of Neuropsychopharmacology 43rd Annual Meeting.
    42. (2005). Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression.
    43. (2003). Low-dose risperidone augmentation of antidepressants in nonpsychotic depressive disorders with suicidal ideation.
    44. (2002). Metanalysis of olanzapinefl uoxetine use in treatment-resistant depression. Eur Neuropsychopharmacol,
    45. (1997). Multiple fi xed doses of “Seroquel’’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo.
    46. (2001). Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder.
    47. (2005). Olanzapine/fl uoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.
    48. (2004). One-year clinical outcomes of depressed public sector outpatients: A benchmark for subsequent studies. Biol Psychiatry, 56:46–53.Neuropsychiatric Disease and Treatment 2007:3(6) 867 A review of quetiapine for depression
    49. (2001). Organization. World Health Report
    50. (2002). Practice Guidelines for the treatment of the patients with Bipolar Disorder (revision).
    51. (1996). Preclinical profi le of seroquel (quetiapine): an atypical antipsychotic with clozapine-like pharmacology. In: Schizophrenia: breaking down the barriers.
    52. (2004). Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depress Anxiety,
    53. (2006). Psychiatry, 66:544.Neuropsychiatric Disease and Treatment 2007:3(6) 866 Daly and Trivedi Gentile S.
    54. (2005). Quetiapine – A review of its use in acute mania and depression associated with bipolar disorder.
    55. (2004). Quetiapine – A review of its use in the management of schizophrenia.
    56. (2001). Quetiapine alone and added to a mood stabilizer for serious mood disorders.
    57. (2006). Quetiapine as treatment of non-psychotic unipolar depression with residual symptoms: a double blind, randomized, placebo-controlled study. American Psychiatric Association annual meeting.
    58. (2006). Quetiapine augmentation for treatment-resistant depression [poster].
    59. (2006). Quetiapine augmentation in treatment-resistant depression: a naturalistic study.
    60. (2006). Quetiapine augmentation of SSRIs/SNRIs in major depression with anxiety [poster].
    61. (2007). Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin,
    62. (2007). Quetiapine in combination with citalopram in patients with unipolar psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry,
    63. (2002). Quetiapine in the treatment of non-psychotic depression
    64. (2004). Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depress Anxiety,
    65. (2006). Quetiapine monotherapy for bipolar II depression: pooled results from two placebo-controlled studies.
    66. (2006). Quetiapine plus SSRI in treatmentresistant depression: possible mechanisms.
    67. (2002). Quetiapine: A 5-year update – Introduction.
    68. (2007). Quetiapine: a review of its use in the treatment of bipolar depression.
    69. (2002). Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing.
    70. (2005). Reevaluating therapies for bipolar depression.
    71. (2000). Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother,
    72. (2003). Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia.
    73. (1999). Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.
    74. (1998). Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome.
    75. (2004). Selection of atypical antipsychotics for the management of schizophrenia.
    76. (2001). The burden of disease for treatment-resistant depression.
    77. (2002). The differential effects of atypical Antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: A pharmacological analysis in rats.
    78. (1989). The dysphoric syndrome in schizophrenia and its implications for relapse.
    79. (2003). The economic burden of depression in the United States: how did it change between
    80. (2000). The effi cacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.
    81. (1996). The global burden of disease.
    82. (1988). The signifi cance of depression in the prediction of relapse in chronic-schizophrenia.
    83. (1999). Treatment resistant depression: methodological overview and operational criteria.
    84. (1995). Treatment resistant depression. In: Psychopharmacology: the fourth generation of progress.
    85. (2006). Treatment strategies after SSRI failure – good news and bad news.
    86. (2005). Use of atypical antipsychotics in refractory depression and anxiety.
    87. (2005). Use of quetiapine in treating nonpsychotic anxiety and depressive disorder.
    88. (2004). Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRIresistant major depressive disorder.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.